Literature DB >> 27194485

Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1.

Vidya Rajendran1.   

Abstract

Arginine to histidine mutation at position 132 (R132H) in isocitrate dehydrogenase 1 (IDH1) led to reduced affinity of the respective enzymes for isocitrate and increased affinity for α-ketoglutarate (AKG) and NADPH. This phenomenon retarded oxidative decarboxylation of isocitrate to AKG and conferred a novel enzymatic activity that facilitated the reduction of AKG to d-2-hydroxyglutarate (d-2HG). The loss of isocitrate utilization and gain of 2HG production from IDH1 R132H had been taken up as a fundamental problem and to solve this, structural biology approaches were adopted. Interaction analysis was carried out to investigate the IDH1 substrate binding environment. The altered behaviour of mutant and native IDH1 in interaction analysis was explored by performing long-term molecular dynamics simulations (∼300 ns). This study reports a comprehensive atomic behaviour of the gain-of-function mutation (R132H) in the IDH1 enzyme which in turn provides a direction towards new therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27194485     DOI: 10.1039/c6mb00182c

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  23 in total

1.  Novel Insights for Inhibiting Mutant Heterodimer IDH1wt-R132H in Cancer: An In-Silico Approach.

Authors:  Ezequiel Iván Juritz; Juan Pablo Bascur; Daniel Eduardo Almonacid; Fernando Danilo González-Nilo
Journal:  Mol Diagn Ther       Date:  2018-06       Impact factor: 4.074

2.  Conformational behavior of coat protein in plants and association with coat protein-mediated resistance against TMV.

Authors:  Jatin Sharma; Rituraj Purohit; Vipin Hallan
Journal:  Braz J Microbiol       Date:  2020-01-13       Impact factor: 2.476

3.  A molecular dynamics approach to explore the structural characterization of cataract causing mutation R58H on human γD crystallin.

Authors:  Rohini Karunakaran; P S Srikumar
Journal:  Mol Cell Biochem       Date:  2018-03-12       Impact factor: 3.396

4.  Comparative study of the unbinding process of some HTLV-1 protease inhibitors using unbiased molecular dynamics simulations.

Authors:  Fereshteh Noroozi Tiyoula; Hassan Aryapour; Mostafa Javaheri Moghadam
Journal:  PLoS One       Date:  2022-07-14       Impact factor: 3.752

5.  Impact of point mutation P29S in RAC1 on tumorigenesis.

Authors:  Vidya Rajendran; Chandrasekhar Gopalakrishnan; Rituraj Purohit
Journal:  Tumour Biol       Date:  2016-10-03

6.  Impact of missense mutations in survival motor neuron protein (SMN1) leading to Spinal Muscular Atrophy (SMA): A computational approach.

Authors:  P Sneha; Tanzila U Zenith; Ummay Salma Abu Habib; Judith Evangeline; D Thirumal Kumar; C George Priya Doss; R Siva; Hatem Zayed
Journal:  Metab Brain Dis       Date:  2018-07-13       Impact factor: 3.584

7.  Structure and dynamics of γ-secretase with presenilin 2 compared to presenilin 1.

Authors:  Budheswar Dehury; Ning Tang; Tom L Blundell; Kasper P Kepp
Journal:  RSC Adv       Date:  2019-07-04       Impact factor: 4.036

8.  Candidate SNP Markers of Chronopathologies Are Predicted by a Significant Change in the Affinity of TATA-Binding Protein for Human Gene Promoters.

Authors:  Petr Ponomarenko; Dmitry Rasskazov; Valentin Suslov; Ekaterina Sharypova; Ludmila Savinkova; Olga Podkolodnaya; Nikolay L Podkolodny; Natalya N Tverdokhleb; Irina Chadaeva; Mikhail Ponomarenko; Nikolay Kolchanov
Journal:  Biomed Res Int       Date:  2016-08-22       Impact factor: 3.411

9.  Influence of MDM2 polymorphisms on squamous cell carcinoma susceptibility: a meta-analysis.

Authors:  Huanxin Yu; Haiyan Li; Jinling Zhang; Gang Liu
Journal:  Onco Targets Ther       Date:  2016-10-11       Impact factor: 4.147

10.  Clinical significance and prospective molecular mechanism of MALAT1 in pancreatic cancer exploration: a comprehensive study based on the GeneChip, GEO, Oncomine, and TCGA databases.

Authors:  Zu-Cheng Xie; Yi-Wu Dang; Dan-Ming Wei; Peng Chen; Rui-Xue Tang; Qian Huang; Jiang-Hua Liu; Dian-Zhong Luo
Journal:  Onco Targets Ther       Date:  2017-08-10       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.